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BAYLISASCARIASIS
Animal
group (s)
affected
Avian
Mammal
Human

Transmission

Ingestion of
embryonated
eggs or
infected
intermediate
hosts

Clinical
Signs
Depression,
lethargy,
agitation,
tremors, head
and/or body
tilt, circling,
ataxia, lateral
recumbency,
coma

Severity

Asympto
matic to
fatal

Treatment

No highly
effective
treatment
exists, ocular
larva migrans
can be killed
using a laser

Prevention
and Control

Zoonotic

Personal/
Yes
environment
hygiene,
wear gloves
when
working
with known
infected
animal/
equipment
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Susceptible animal groups Avian, Mammal, Human
Causative organism
Recognized species of Baylisascaris
Parasite
Primary Definitive Host(s)
B. procyonis
Raccoons and other procyonids (e.g., kinkajou)
B. columnaris
Skunks
B. melis
Badgers
B. devosi
Martens, fishers
B. transfuga
Bears
B. schroederi
Giant pandas
B. tasmaniensis
Tasmanian devils, quolls, native “cats”
B. laevis
Marmots, ground squirrels
Zoonotic potential Yes
Distribution
Baylisascaris procyonis is a common parasite of raccoons (Procyon lotor) in several
regions of the United States and Canada and has been introduced with raccoons to Japan
and several countries in Europe. In the United States, the highest prevalence rates occur
in the Midwestern, Northeastern, and Western states. In the Southeastern U.S., infections
are more common in mountainous regions; but has been found in isolated areas of
Georgia and Florida. In Canada, B. procyonis is found in British Columbia, Nova Scotia,
Ontario, Prince Edward Island, and Quebec.
Current distribution maps are unavailable for the majority of other known Baylisascaris
spp. within the U.S. and Canada, B. columnaris, B. melis, and B. transfuga likely pose a
zoonotic risk to humans and are probably found throughout the range of their natural
hosts.
Incubation period
Once ingested, larvae may migrate through numerous tissues, including the brain, as
early as 3 days post infection. In susceptible species, central nervous system disease can

be observed 9-10 days post-infection. In more resistant species or if low numbers of
larvae are ingested, CNS symptoms may not appear until 2-4 + weeks post-infection.
Clinical signs
Clinical signs in intermediate hosts, including humans, vary based on number of larvae
ingested, the tissues through which larvae migrate, and species of host. Pathogenicity
varies among Baylisascaris sp. B. procyonis and B. melis are the most pathogenic,
followed by B. columaris and little is known about other Baylisascaris spp.. Clinical
signs may include, but are not limited to, depression, lethargy, tremors, partial paralysis,
head or body tilts, ataxia, circling, mental delays, easy agitation/ irritability, and death.
Post mortem, gross, or histologic findings
Many effected animals will have no gross lesions. However, inflammation and traumatic
damage may be observed through the liver, lungs, and other organs of animals infected
with large numbers of larvae. In these hosts, granulomas may be grossly visible in many
tissues such as the liver, lungs, heart, diaphragm, pancreas, spleen, kidneys, mesentery,
mesenteric lymph nodes, intestinal wall, skeletal muscles, brain, and eyes.
Histologically, extensive inflammatory tracts and larvae may be observed.
Diagnosis
Humans: Highly suspect Baylisascaris infections can be diagnosed using serologic
methods such as indirect immunofluorescence, ELISA, and Western blotting.
Animals: Postmortem necropsies of suspected animals are the most conclusive way to
diagnose Baylisascaris infections. In suspected intermediate hosts, clinical signs, history
of exposure, serology, post mortem necropsies, and recovery and/or identification of
larvae can be used to diagnose Baylisascaris. Fecal floats or necropsy and examination
of small intestine can be used to diagnose infection in definitive hosts. For treatment,
several types of anthelmintics are 95-99% effective.
Material required for laboratory analysis
Adult nematode specimens may be examined microscopically and identified
morphologically although adult males are needed to determine species. Genetic
identification may be needed for larva migrans found in intermediate hosts and/or
immature nematodes in definitive hosts.
Relevant diagnostic laboratories
Veterinary clinics can run routine fecal exams to diagnose infection in definitive hosts. In
intermediate hosts, veterinary diagnostic laboratories capable of PCR analysis and/or
histology should be able to perform diagnostic testing on suspected animal cases. Human
cases should be referred to the Health Department or the CDC for testing.
Treatment
Currently there is no highly effective treatment for larva migrans associated with B.
procyonis in humans. Ocular larva migrans can be killed using lasers followed by a
regime of anti-inflammatory drugs and steroids to aid in the possible recovery of any
remaining visual acuity.
Raccoons, skunks, dogs, and bears can be successfully treated with common
antihelmintics such as pyrantel pamonate (20 mg/kg), ivermectin (1 mg/kg), moxidectin
(1 mg/kg), albendazole (50 mg/kg x 3 days), fenbendazole (50 mg/kg x 3 days), and
flubendazole (22mg/kg x 3 days). Animals should be monitored regularly after treatment
to ensure complete clearance of worms.
Prevention and control

Continued education of the public, human health, wildlife, and veterinary professionals
should be made a priority. Recent research using antihelmintic baits combined with the
removal of latrine sites has shown to decrease prevalence rates among intermediate hosts.
Further research is needed to determine the exact distribution, potential for spread,
transmission dynamics, and impacts on wildlife.
Suggested disinfectant for housing facilities
Areas should be cleaned immediately to avoid accidental ingestion of eggs by children or
pets. Eggs are not immediately infectious and must develop in the environment for a
period of time (11-14 days) before becoming infective. Frequent sanitation will limit the
buildup of eggs on these surfaces. However, eggs will continue to accumulate in the
surrounding environment and once the eggs embryonate, they can remain viable for
several years.
Currently few methods are available for decontaminating areas infested with B. procyonis
eggs. Highly concentrated caustic chemicals such as a 50/50 mixture of xylene and
absolute alcohol, boiling lye, or boiling Lysol may be used to decontaminate potentially
infected areas. The most effective way of decontaminating an area is flaming an area.
Although burning is the most effective way to kill eggs, it is not useful for flammable
areas such as roofs, decks, etc. In the laboratory, boiling water has been shown to kill
eggs.
Notification
Baylisascariasis in humans is reportable in some states; check your local requirements.
Infection in animals is not reportable.
Measures required under the Animal Disease Surveillance Plan None
Measures required for introducing animals to infected animal
Animals displaying neurologic symptoms are not infective to other intermediate hosts.
However, impaired intermediate hosts are likely to become prey for various carnivore
species. If ingested by an appropriate definitive host, the parasite cycle within a system
could be perpetuated.
Definitive hosts known to harbor infections should be quarantined, placed on an
antihelmintic regime, and monitored regularly for infection. Before placing susceptible
animals in cages that had contact with infected animals, the cages should be
decontaminated.
Conditions for restoring disease-free status after an outbreak None
Experts who may be consulted
Michael J. Yabsley
Associate Professor
589 D.W. Brooks Drive
Southeastern Cooperative Wildlife Disease Study
College of Veterinary Medicine
University of Georgia
Athens, Georgia 30602
Office: (706) 542-1741
myabsley@uga.edu
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